These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 39128004)

  • 1. Mutant TP53 switches therapeutic vulnerability during gastric cancer progression within interleukin-6 family cytokines.
    Huber A; Allam AH; Dijkstra C; Thiem S; Huynh J; Poh AR; Konecnik J; Jacob SP; Busuttil R; Liao Y; Chisanga D; Shi W; Alorro MG; Forrow S; Tauriello DVF; Batlle E; Boussioutas A; Williams DS; Buchert M; Ernst M; Eissmann MF
    Cell Rep; 2024 Aug; 43(8):114616. PubMed ID: 39128004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.
    Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK
    PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer.
    Wu R; Baker SJ; Hu TC; Norman KM; Fearon ER; Cho KR
    Am J Pathol; 2013 Apr; 182(4):1391-9. PubMed ID: 23499052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STAT3 is Activated by CTGF-mediated Tumor-stroma Cross Talk to Promote HCC Progression.
    Makino Y; Hikita H; Kato S; Sugiyama M; Shigekawa M; Sakamoto T; Sasaki Y; Murai K; Sakane S; Kodama T; Sakamori R; Kobayashi S; Eguchi H; Takemura N; Kokudo N; Yokoi H; Mukoyama M; Tatsumi T; Takehara T
    Cell Mol Gastroenterol Hepatol; 2023; 15(1):99-119. PubMed ID: 36210625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer.
    Morton JP; Timpson P; Karim SA; Ridgway RA; Athineos D; Doyle B; Jamieson NB; Oien KA; Lowy AM; Brunton VG; Frame MC; Evans TR; Sansom OJ
    Proc Natl Acad Sci U S A; 2010 Jan; 107(1):246-51. PubMed ID: 20018721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of Gastric Cancer by Successive Oncogenic Activation in the Corpus.
    Douchi D; Yamamura A; Matsuo J; Melissa Lim YH; Nuttonmanit N; Shimura M; Suda K; Chen S; Pang S; Kohu K; Abe T; Shioi G; Kim G; Shabbir A; Srivastava S; Unno M; Bok-Yan So J; Teh M; Yeoh KG; Chuang LSH; Ito Y
    Gastroenterology; 2021 Dec; 161(6):1907-1923.e26. PubMed ID: 34391772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmented gp130-mediated cytokine signalling accompanies human gastric cancer progression.
    Jackson CB; Judd LM; Menheniott TR; Kronborg I; Dow C; Yeomans ND; Boussioutas A; Robb L; Giraud AS
    J Pathol; 2007 Oct; 213(2):140-51. PubMed ID: 17724739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo.
    Mullany LK; Fan HY; Liu Z; White LD; Marshall A; Gunaratne P; Anderson ML; Creighton CJ; Xin L; Deavers M; Wong KK; Richards JS
    Oncogene; 2011 Aug; 30(32):3522-36. PubMed ID: 21423204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mouse Models of Human Gastric Cancer Subtypes With Stomach-Specific CreERT2-Mediated Pathway Alterations.
    Seidlitz T; Chen YT; Uhlemann H; Schölch S; Kochall S; Merker SR; Klimova A; Hennig A; Schweitzer C; Pape K; Baretton GB; Welsch T; Aust DE; Weitz J; Koo BK; Stange DE
    Gastroenterology; 2019 Dec; 157(6):1599-1614.e2. PubMed ID: 31585123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three types of metaplasia model through Kras activation, Pten deletion, or Cdh1 deletion in the gastric epithelium.
    Kinoshita H; Hayakawa Y; Konishi M; Hata M; Tsuboi M; Hayata Y; Hikiba Y; Ihara S; Nakagawa H; Ikenoue T; Ushiku T; Fukayama M; Hirata Y; Koike K
    J Pathol; 2019 Jan; 247(1):35-47. PubMed ID: 30168144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of IL-11 promotes premalignant gastric epithelial hyperplasia in isolation from germline gp130-JAK-STAT driver mutations.
    Buzzelli JN; O'Connor L; Scurr M; Chung Nien Chin S; Catubig A; Ng GZ; Oshima M; Oshima H; Giraud AS; Sutton P; Judd LM; Menheniott TR
    Am J Physiol Gastrointest Liver Physiol; 2019 Feb; 316(2):G251-G262. PubMed ID: 30520693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant p53 Promotes Epithelial Ovarian Cancer by Regulating Tumor Differentiation, Metastasis, and Responsiveness to Steroid Hormones.
    Ren YA; Mullany LK; Liu Z; Herron AJ; Wong KK; Richards JS
    Cancer Res; 2016 Apr; 76(8):2206-18. PubMed ID: 26964623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stomach-Specific Activation of Oncogenic KRAS and STAT3-Dependent Inflammation Cooperatively Promote Gastric Tumorigenesis in a Preclinical Model.
    Thiem S; Eissmann MF; Elzer J; Jonas A; Putoczki TL; Poh A; Nguyen P; Preaudet A; Flanagan D; Vincan E; Waring P; Buchert M; Jarnicki A; Ernst M
    Cancer Res; 2016 Apr; 76(8):2277-87. PubMed ID: 26837764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice.
    Ogawa S; Fukuda A; Matsumoto Y; Hanyu Y; Sono M; Fukunaga Y; Masuda T; Araki O; Nagao M; Yoshikawa T; Goto N; Hiramatsu Y; Tsuda M; Maruno T; Nakanishi Y; Hussein MS; Tsuruyama T; Takaori K; Uemoto S; Seno H
    Gastroenterology; 2020 Aug; 159(2):682-696.e13. PubMed ID: 32360551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation.
    Nakayama M; Sakai E; Echizen K; Yamada Y; Oshima H; Han TS; Ohki R; Fujii S; Ochiai A; Robine S; Voon DC; Tanaka T; Taketo MM; Oshima M
    Oncogene; 2017 Oct; 36(42):5885-5896. PubMed ID: 28628120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
    Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
    Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.
    Nowak DG; Cho H; Herzka T; Watrud K; DeMarco DV; Wang VM; Senturk S; Fellmann C; Ding D; Beinortas T; Kleinman D; Chen M; Sordella R; Wilkinson JE; Castillo-Martin M; Cordon-Cardo C; Robinson BD; Trotman LC
    Cancer Discov; 2015 Jun; 5(6):636-51. PubMed ID: 25829425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTEN loss and KRAS activation leads to the formation of serrated adenomas and metastatic carcinoma in the mouse intestine.
    Davies EJ; Marsh Durban V; Meniel V; Williams GT; Clarke AR
    J Pathol; 2014 May; 233(1):27-38. PubMed ID: 24293351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEK inhibition suppresses metastatic progression of KRAS-mutated gastric cancer.
    Yamasaki J; Hirata Y; Otsuki Y; Suina K; Saito Y; Masuda K; Okazaki S; Ishimoto T; Saya H; Nagano O
    Cancer Sci; 2022 Mar; 113(3):916-925. PubMed ID: 34931404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interleukin-6 family cytokine interleukin-11 regulates homeostatic epithelial cell turnover and promotes gastric tumor development.
    Howlett M; Giraud AS; Lescesen H; Jackson CB; Kalantzis A; Van Driel IR; Robb L; Van der Hoek M; Ernst M; Minamoto T; Boussioutas A; Oshima H; Oshima M; Judd LM
    Gastroenterology; 2009 Mar; 136(3):967-77. PubMed ID: 19121317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.